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also the case for the ESS score in sleepy patients (p = 0.007). 
 Conclusion: In our series of RLS patients, EDS was common, 
characterized by longer sleep (PSG) and reduced sleep laten-
cies on MSLT. Under dopaminergic treatment, both RLS se-
verity and ESS improved.  Copyright © 2009 S. Karger AG, Basel 
 Introduction  
 The restless legs syndrome (RLS) is a common neuro-
logical sleep disorder affecting 0.5–10% of the general 
population  [1–3] , which is twice as common in women 
than in men  [4, 5] . The International RLS Study Group 
defined four minimal diagnostic criteria  [5–7] , and sup-
portive criteria include (1) a positive family history of 
RLS, (2) a positive response to dopaminergic therapy and 
(3) periodic limb movements (PLM) during wakefulness 
or sleep (PLMS). PLMS occur in about 80% of RLS pa-
tients  [8] . RLS is a heterogeneous disorder and can be id-
iopathic, familiar or symptomatic mainly in association 
with iron deficiency, pregnancy, anemia or uremia  [9–11] . 
RLS symptoms and PLMS often disrupt the night sleep 
and impair sleep quality. Whereas insomnia is a frequent 
complaint in RLS  [3, 8, 12] , there is little knowledge about 
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 Abstract 
 Background/Aims: Whereas insomnia is frequent in restless 
legs syndrome (RLS), little is known about daytime sleepi-
ness. We studied a series of 27 consecutive patients with 
 idiopathic RLS in order to identify the characteristics and 
evolution of excessive daytime sleepiness (EDS) under do-
paminergic treatment.  Methods: Patients were assessed by 
clinical examination, questionnaires and video-polysom-
nography (PSG). Sleepy patients, as defined by Epworth 
Sleepiness Scale (ESS)  1 10, were also assessed by the multi-
ple sleep latency test (MSLT). We excluded RLS patients with 
other sleep-wake disorders, in particular chronic sleep de-
privation.  Results: Mean age was 56 years, the mean Inter-
national RLS Study Group Rating Scale score was 24 at base-
line. Ten (37%) of the 27 patients reported EDS. RLS patients 
with sleepiness had a higher amount of total sleep time (p = 
0.029) on PSG and a mean sleep latency of 6.4 min on MSLT. 
No other differences regarding clinical or polysomnograph-
ic parameters were found. RLS severity improved in all pa-
tients under dopaminergic treatment (p = 0.001); this was 
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determinants of excessive daytime sleepiness (EDS) as 
well as its evolution under dopaminergic treatment  [12] . 
In five previous studies, a subpopulation of RLS patients 
with daytime sleepiness [Epworth Sleepiness Scale (ESS) 
 1 10] has been identified  [3, 13–16] . Two studies looked at 
the association of dopaminergic treatment and sleepiness 
in RLS patients  [17, 18] . The aim of this study was to as-
sess characteristics of RLS with EDS and to evaluate the 
evolution of EDS under dopaminergic treatment. 
 Patients and Methods 
 Ethical Aspects 
 The study has been reviewed and approved by the Institution-
al Review Boards.
 Clinical Assessment 
 The data of 27 consecutive patients (13 men) with untreated 
idiopathic RLS were retrospectively analyzed. Additional sleep-
wake disorders (e.g. narcolepsy and sleep-disordered breathing), 
chronic sleep deprivation, in particular behaviorally induced in-
sufficient sleep syndrome, and major systemic, neurological and 
psychiatric disorders were excluded by medical history, clinical 
examination, questionnaires (e.g. International RLS Study Group 
Rating Scale (IRLS) and ESS), video-polysomnography (PSG) and 
blood tests (including iron, renal and thyroid parameters). All 
patients were free of any CNS medication. EDS was defined as ESS 
 1 10  [19] , and severe EDS as ESS  1 14. 
 Nocturnal Sleep Studies 
 A conventional PSG including four-channel EEG and left and 
right anterior tibialis electromyography were performed in all pa-
tients (Medcare Somnologica Studio software, version 3.2). Sleep 
stages  [20] and arousals were scored manually, and apneas/hy-
popneas and PLM were reanalyzed automatically and checked vi-
sually, all according to international criteria. Sleep onset was de-
fined as the first epoch of rapid eye movement or non-rapid eye 
movement 2–4 sleep. RLS patients with EDS (n = 10) were also 
assessed by the multiple sleep latency test (MSLT)  [21] after the 
PSG night.
 Treatment 
 All patients received dopaminergic treatment, e.g. pramipex-
ole (n = 12, mean dose 0.56 mg/day), ropinirole (n = 8, 0.63 mg/
day) and others (cabergoline; n = 4, 1.25 mg/day, and pergolide;
n = 3, 0.67 mg/day) after the initial assessment and were assessed 
clinically again including sleep questionnaires (IRLS and ESS) 2 
months later. In 3 of the 10 sleepy patients, MSLT was repeated 
under treatment. 
 Data Analysis 
 Statistical analysis was performed using SPSS software (ver-
sion 13). Due to the small data set, we used non-parametric tests 
(e.g. the Mann-Whitney test) to compare the independent groups 
of sampled data. Significance was defined as p  ! 0.05.
 Results  
 Clinical Features 
 The main demographic characteristics, ESS, IRLS, 
 PSG and MSLT data are presented in  table 1 . The mean 
IRLS score was 24.2 at baseline and improved to a mean 
of 16.9 (p  ! 0.001) under dopaminergic treatment. Fe-
males had a higher IRLS score (26.6 vs. 21.7 in men, p = 
0.031) at baseline. EDS was found in 10 (37%) and was se-
vere in 6 (22%) of the 27 patients. 
 Sleep Studies 
 Sleepy RLS patients had a higher amount of total sleep 
time (TST) on PSG (378 vs. 313 min; p = 0.029;  table 1 ). 
During treatment, mean sleep latency increased in all 3 
patients by a mean of 1.8 min ( 8 1.2). 
 Dopaminergic Treatment 
 At the 2-month follow - up, ESS was significantly lower 
only in sleepy RLS patients (p = 0.007). In 4 of our pa-
tients, ESS increased under treatment (pramipexole, n = 
2, and ropinirole, n = 2). Three of them were in the group 
of the non-sleepy RLS patients (mean ESS: 7.3 at baseline 
and 9.7 under treatment). One patient was within the 
sleepy group (mean ESS: 11 at baseline and 13 during 
treatment). No sleep attacks occurred. 
 Discussion 
 Our results are in line with previous findings  [12–16] 
indicating the existence of a substantial subgroup of RLS 
patients with EDS. Sleepy RLS patients also exhibited 
other features of hypersomnia, e.g. longer TST on PSG. 
 The existence of EDS and hypersomniac features in 
our series of RLS patients cannot be explained by coexist-
ing sleep disorders, differences in demographics, clinical 
features, overnight sleep, PLMS, arousal index or medi-
cation. Insufficient sleep (e.g. the behaviorally induced 
insufficient sleep syndrome), one of the most common 
causes of EDS, was excluded by medical history and sleep 
questionnaires. 
 No significant differences were found between sleepy 
and non-sleepy patients. In contrast to the literature  [14, 
15] , in our patients no association between the frequency 
of RLS symptoms and EDS or insomnia and EDS was 
found. 
 The origin of EDS in RLS remains unknown. Dopa-
mine plays an important role in the modulation of sleep 
and wakefulness  [22] . Insufficient dopamine transmis-
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sion has been implicated in the pathophysiology of RLS 
 [23] and has been suggested to be involved in EDS of oth-
er sleep disorders. Neurochemical studies in the cerebro-
spinal fluid suggested that patients with idiopathic hy-
persomnia might have an altered monoaminergic system 
as possible sign of a dopaminergic dysfunction  [24] . In 
addition, dopamine antagonists usually exacerbate RLS 
symptoms and EDS. The possibility of an insufficient do-
paminergic transmission is supported by the observation 
that all evaluated agents that enhance dopamine activity 
reduce RLS symptoms  [10] . 
 Indeed, also in our study, dopaminergic treatment was 
efficient for RLS symptoms (assessed by IRLS), but also 
for EDS in sleepy patients (assessed by ESS and mean 
sleep latency). This finding is in contrast to Parkinson’s 
disease, where dopamine therapy often leads to sleepi-
ness. Nevertheless, also in our study there were 4 patients, 
mainly from the non-sleepy group, where sleepiness in-
creased under dopaminergic treatment. No sleep attacks 
occurred  [18, 25] . These observations point to the neces-
sity to take EDS into consideration in non-treated and 
treated RLS patients. 
 A retrospective study bears potential bias when assess-
ing the treatment effect, which is in our case dopaminer-
gic treatment. 
 In conclusion, in our series of RLS patients, EDS was 
common (occasionally severe) and could be objectively 
confirmed by MSLT. Dopaminergic treatment improved 
RLS symptoms and EDS. We suggest the existence of a 
subgroup of sleepy and even ‘hypersomniac’ RLS patients 
in whom EDS is possibly due to a dopaminergic dysfunc-
tion different from the pathogenetic mechanism of RLS 
in non-sleepy patients. 
Table 1. Main demographic characteristics, ESS, IRLS, MSLT and PSG results at baseline and follow-up (ESS 
and IRLS)
All patients
(n = 27)
Non-sleepy
(n = 17)
Sleepy
(n = 10)
p value
sleepy vs. non-sleepy
Age 56.4811 56.4813 56.487 NS
Body mass index 25.183.4 25.583.4 24.483.5 NS
IRLS 24.285.6 24.784.8 23.387 NS
ESS 9.984.1 7.182.2 14.581.5 <0.001
IRLS at follow-up 16.987.1 17.188 16.685 NS
ESS at follow-up 7.584 5.984 10.283 0.004
PSG
Sleep latency N2, min 36.9855 50.7865 13.4812 NS
Sleep latency REM, min 106.6860.2 97.7861 122859 NS
Total sleep time, min 336.7875 313882 378838 0.03
PLMS index (TST) 26.6817.9 27.1821 25.6811 NS
Arousal index (TIB) 12.9810.5 11.989 14.5813 NS
Sleep efficiency, % of TIB 83812.1 83.3810 82.4815 NS
NREM1 sleep, % of TST 10.286.2 10.888 9.183 NS
NREM2 sleep, % of TST 48.1810.4 47.589 49.1813 NS
Slow-wave sleep, % of TST 12.388.7 13.6810 9.987 NS
REM sleep, % of TST 12.285.9 11.187 1484 NS
Wake, % of TIB 16.9811.6 16.2810 18.2815 NS
MSLT (n = 10)
MSL, min – – 6.482.7 –
Patients with MSL <5 min, n – – 3 –
Patients with SOREM, n – – 1 –
Means 8 SD. REM = Rapid eye movement; TIB = time in bed; NREM1/2 = non-REM sleep stage 1/2; 
SOREM = sleep-onset REM period(s).
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